Genetic determinants of malignancy in a mouse model for oligodendroglioma.

Oligodendrogliomas of all grades overexpress epidermal growth factor receptor (EGFR), whereas deletion of ink4a/arf is found only in high-grade tumors. We used the S100 beta promoter to generate transgenic mice expressing v-erbB, a transforming allele of EGFR. These mice developed low-grade oligodendroglioma. Transgenic animals heterozygous for ink4a/arf or p53 developed high-grade tumors. Comparative genomic hybridization revealed loss of distal mouse chromosome 4, a region orthologous with human chromosome 1p, which is commonly lost in oligodendroglioma. Our results demonstrate that overexpression of EGFR, an epigenetic observation of uncertain significance in human oligodendroglioma, can initiate oligodendroglioma in the mouse. Furthermore, p53 pathway mutations can mediate the transition from low to high grade. These models hold promise for studying tumor lineage, identifying contributing genetic alterations and evaluating preclinical therapies in this important neoplasm.

[1]  P. Yarowsky,et al.  Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Schröck,et al.  Recurrent gain of chromosome arm 7q in low‐grade astrocytic tumors studied by comparative genomic hybridization , 1996, Genes, chromosomes & cancer.

[3]  P. Kleihues,et al.  p53 mutations in nonastrocytic human brain tumors. , 1991, Cancer research.

[4]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Hoang-Xuan,et al.  OLIG‐1 and 2 gene expression and oligodendroglial tumours , 2002, Neuropathology and applied neurobiology.

[6]  B. Scheithauer,et al.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Louis,et al.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.

[8]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[10]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[11]  Jean-Yves Delattre,et al.  OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.

[12]  Alan J. Wilson,et al.  The blood-brain barrier: an important concept in neuroimaging. , 1994, AJNR. American journal of neuroradiology.

[13]  S. Lowe,et al.  p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.

[14]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[15]  V. P. Collins,et al.  Epidermal growth factor receptor expression in oligodendroglial tumors. , 1996, The American journal of pathology.

[16]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[17]  F. Zhou,et al.  Long‐term nonpassaged EGF‐responsive neural precursor cells are stem cells , 1998, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[18]  D. Rowitch,et al.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Bleyer,et al.  Epidemiologic impact of children with brain tumors , 1999, Child's Nervous System.

[20]  I. Petersen,et al.  Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. , 1992, Cancer research.

[21]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[22]  Bleyer Wa Epidemiologic impact of children with brain tumors. , 1999 .

[23]  C. Sommer,et al.  Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. , 1996, Oncogene.

[24]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[25]  J. Kononen,et al.  CDKN2/p16 Predicts Survival in Oligodendrogliomas: Comparison with Astrocytomas , 1999, Journal of Neuro-Oncology.

[26]  L. Ellis,et al.  Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. , 2000, Cancer research.

[27]  J. Wolff,et al.  S100 immunoreactivity in a subpopulation of oligodendrocytes and Ranvier's nodes of adult rat brain , 1995, Neuroscience Letters.

[28]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[29]  D. Hilt,et al.  Organization, sequence, and expression of the murine S100 beta gene. Transcriptional regulation by cell type-specific cis-acting regulatory elements. , 1993, The Journal of biological chemistry.

[30]  L. D.,et al.  Brain tumors , 2005, Psychiatric Quarterly.

[31]  S. Ludwin,et al.  The topographical distribution of S‐100 and GFA proteins in the adult rat brain: An immunohistochemical study using horseradish peroxidase‐labelled antibodies , 1976, The Journal of comparative neurology.

[32]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[33]  G S Bauman,et al.  Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. , 2000, International journal of radiation oncology, biology, physics.

[34]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[35]  G. Evan,et al.  Orientation of the v-erb-B gene product in the plasma membrane , 1986, Molecular and cellular biology.

[36]  Daniel A. Lim,et al.  Subventricular Zone Astrocytes Are Neural Stem Cells in the Adult Mammalian Brain , 1999, Cell.

[37]  P. Gass,et al.  Expression of oligodendroglia and Schwann cell markers in human nervous system tumors , 1992, Acta Neuropathologica.

[38]  B. Scheithauer,et al.  Oligodendroglioma: the ultrastructural spectrum. , 1994, Ultrastructural pathology.

[39]  J. Hogg Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.

[40]  R. Hume,et al.  Glial and neuronal differentiation in the human fetal brain 9–23 weeks of gestation , 1990, Neuropathology and applied neurobiology.

[41]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.